Prevail Therapeutics
Clinical trials sponsored by Prevail Therapeutics, explained in plain language.
-
New Parkinson's drug candidate enters early human safety trials
Disease control Recruiting nowThis early-stage study tests a new drug called LY3962681 for safety and how the body processes it. First, healthy volunteers get a single dose into their spinal fluid. Then, people with Parkinson's disease get two doses, spaced months apart. The goal is to see if the drug is safe…
Phase: PHASE1 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Could a single shot replace daily gaucher meds?
Disease control Recruiting nowThis study tests a one-time gene therapy (LY3884961) for adults with Gaucher disease type 1. The goal is to see if it is safe and can reduce or stop the need for current enzyme replacement or substrate reduction therapy. About 15 participants will receive a single intravenous dos…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:05 UTC